UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 2, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At November 7, 2016, 6,068,355,132 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended October 2, 2016 and September 27, 2015

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 2, 2016 and September 27, 2015

Condensed Consolidated Balance Sheets as of October 2, 2016 and December 31, 2015

Condensed Consolidated Statements of Cash Flows for the nine months ended October 2, 2016 and September 27, 2015

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

50

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

51

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

107

Item 4.

Controls and Procedures

107

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

108

Item 1A.

Risk Factors

108

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

109

Item 3.

Defaults Upon Senior Securities

109

Item 4.

Mine Safety Disclosures

109

Item 5.

Other Information

109

Item 6.

Exhibits

110

Signature

111

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2015 Financial Report

Financial Report for the fiscal year ended December 31, 2015, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2015

2015 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2015

AAV

Adeno-Associated Virus

ACA

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Allergan

Allergan plc

Alliance revenues

revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AM-Pharma

AM-Pharma B.V.

Anacor

Anacor Pharmaceuticals, Inc.

Astellas

Astellas Pharma Inc.

ASU

Accounting Standards Update

ATM-AVI

aztreonam-avibactam

Bamboo

Bamboo Therapeutics, Inc.

Baxter

Baxter International Inc.

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

Celltrion

Celltrion Inc. and Celltrion Healthcare, Co., Ltd. (collectively)

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, Scandinavia, South Korea, Finland and New Zealand

DEUs

Dividend Equivalent Units

DVT

deep vein thrombosis

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GHD

growth hormone deficiency

GIST

gastrointestinal stromal tumors

GIP

Global Innovative Pharmaceutical segment

GPD

Global Product Development organization

GS&Co.

Goldman, Sachs & Co.

HER2-

human epidermal growth factor receptor 2-negative

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical Inc.

IH

Innovative Health

InnoPharma

InnoPharma, Inc.

IPR&D

in-process research and development

IRC

Internal Revenue Code

IRS

U.S. Internal Revenue Service

Janssen

Janssen Biotech Inc.

King

King Pharmaceuticals, Inc.

LDL

low density lipoprotein

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCO

managed care organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

MDV

multi-dose vial

Medivation

Medivation, Inc.

Moody s

Moody s Investors Service

mRCC

metastatic renal cell carcinoma

NDA

new drug application

NOAC

Novel Oral Anticoagulant

NovaQuest

NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PBM

Pharmacy Benefit Manager

PCS

Pfizer CenterOne (previously known as Pfizer CentreSource)

PDUFA

Prescription Drug User Fee Act

PE

pulmonary embolism

PGS

Pfizer Global Supply

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

PTUs

Profit Units

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2016

RAR

Revenue Agent s Report

RCC

renal cell carcinoma

recAP

recombinant human Alkaline Phosphatase

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SGA

small for gestational age

S&P

Standard and Poor s

Teuto

Laborat rio Teuto Brasileiro S.A.

TSRUs

Total Shareholder Return Units

U.K.

United Kingdom

U.S.

United States

VAT

value added tax

VOC

Global Vaccines, Oncology and Consumer Healthcare segment

WRD

Worldwide Research and Development

Zoetis

Zoetis Inc.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

October 2,

2016

September 27,

2015

October 2,

2016

September 27,

2015

Revenues

13,045

12,087

39,196

34,804

Costs and expenses:

Cost of sales(a)

3,085

2,219

9,111

6,238

Selling, informational and administrative expenses(a)

3,559

3,270

10,414

9,761

Research and development expenses(a)

1,881

1,722

5,360

5,342

Amortization of intangible assets

968

937

2,934

2,748

Restructuring charges and certain acquisition-related costs

531

581

988

727

Other (income)/deductions net

1,417

661

2,815

670

Income from continuing operations before provision for taxes on income

1,604

2,697

7,575

9,319

Provision for taxes on income

284

567

1,194

2,178

Income from continuing operations

1,320

2,130

6,380

7,141

Discontinued operations net of tax

14

Net income before allocation to noncontrolling interests

1,319

2,139

6,380

7,155

Less: Net income attributable to noncontrolling interests

25

23

Net income attributable to Pfizer Inc.

1,320

2,130

6,355

7,132

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.22

0.34

1.04

1.15

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.22

0.35

1.04

1.15

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.22

0.34

1.03

1.14

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.21

0.34

1.03

1.14

Weighted-average shares basic

6,066

6,168

6,095

6,176

Weighted-average shares diluted

6,138

6,243

6,164

6,259

Cash dividends paid per common share

0.30

0.28

0.90

0.84

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

October 2,

2016

September 27,

2015

October 2,

2016

September 27,

2015

Net income before allocation to noncontrolling interests

1,319

2,139

6,380

7,155

Foreign currency translation adjustments, net

418

(535

999

(2,170

418

(535

999

(2,170

Unrealized holding losses on derivative financial instruments, net

(126

(217

(970

(80

Reclassification adjustments for realized (gains)/losses(a)

150

(35

280

(545

24

(251

(690

(625

Unrealized holding gains/(losses) on available-for-sale securities, net

261

25

740

(502

Reclassification adjustments for realized (gains)/losses(a)

(112

69

(129

815

149

94

611

312

Benefit plans: actuarial losses, net

(82

(144

(101

(122

Reclassification adjustments related to amortization(b)

140

140

418

409

Reclassification adjustments related to settlements, net(b)

28

36

76

98

Other

69

(10

51

120

155

23

444

506

Benefit plans: prior service credits and other, net

95

182

506

Reclassification adjustments related to amortization(b)

(45

(46

(127

(115

Reclassification adjustments related to curtailments, net(b)

(8

(4

(14

(21

Other

(1

12

(3

48

(51

54

366

Other comprehensive income/(loss), before tax

794

(721

1,418

(1,611

Tax provision/(benefit) on other comprehensive income/(loss)(c)

116

(65

111

267

Other comprehensive income/(loss) before allocation to noncontrolling interests

678

(656

1,307

(1,878

Comprehensive income before allocation to noncontrolling interests

1,997

1,483

7,687

5,277

Less: Comprehensive income/(loss) attributable to noncontrolling interests

24

(1

Comprehensive income attributable to Pfizer Inc.

1,997

1,481

7,664

5,278

(a)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(b)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(c)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

October 2,

2016

December 31,

2015

(Unaudited)

Assets

Cash and cash equivalents

2,094

3,641

Short-term investments

12,277

19,649

Trade accounts receivable, less allowance for doubtful accounts: 2016 $672; 2015 $384

9,836

8,176

Inventories

7,507

7,513

Current tax assets

2,825

2,662

Other current assets

2,843

2,154

Assets held for sale

1,119

Total current assets

38,501

43,804

Long-term investments

9,507

15,999

Property, plant and equipment, less accumulated depreciation: 2016 $14,838; 2015 $13,502

13,284

13,766

Identifiable intangible assets, less accumulated amortization

54,238

40,356

Goodwill

56,281

48,242

Noncurrent deferred tax assets and other noncurrent tax assets

1,859

1,794

Other noncurrent assets

4,759

3,420

Total assets

178,430

167,381

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

13,633

10,159

Trade accounts payable

3,476

3,620

Dividends payable

1,821

1,852

Income taxes payable

1,158

418

Accrued compensation and related items

2,048

2,359

Other current liabilities

12,623

10,990

Total current liabilities

34,759

29,399

Long-term debt

30,437

28,740

Pension benefit obligations, net

5,312

6,310

Postretirement benefit obligations, net

1,808

1,809

Noncurrent deferred tax liabilities

31,687

26,877

Other taxes payable

4,767

3,992

Other noncurrent liabilities

6,059

5,257

Total liabilities

114,829

102,384

Commitments and Contingencies

Preferred stock

25

26

Common stock

461

459

Additional paid-in capital

82,534

81,016

Treasury stock

(84,346

(79,252

Retained earnings

72,846

71,993

Accumulated other comprehensive loss

(8,214

(9,522

Total Pfizer Inc. shareholders equity

63,306

64,720

Equity attributable to noncontrolling interests

294

278

Total equity

63,601

64,998

Total liabilities and equity

178,430

167,381

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS OF DOLLARS)

October 2,

2016

September 27,

2015

Operating Activities

Net income before allocation to noncontrolling interests

6,380

7,155

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

4,208

3,733

Asset write-offs and impairments

1,146

864

Write-down of HIS net assets to fair value less estimated costs to sell

1,422

Deferred taxes from continuing operations

(1,335

(165

Share-based compensation expense

532

488

Benefit plan contributions in excess of expense

(775

(804

Other adjustments, net

68

(184

Other changes in assets and liabilities, net of acquisitions and divestitures

(1,718

(1,297

Net cash provided by operating activities

9,929

9,790

Investing Activities

Purchases of property, plant and equipment

(1,134

(786

Purchases of short-term investments

(15,170

(21,068

Proceeds from redemptions/sales of short-term investments

20,685

33,609

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

6,485

5,557

Purchases of long-term investments

(4,771

(6,578

Proceeds from redemptions/sales of long-term investments

6,915

4,535

Acquisitions of businesses, net of cash acquired

(17,679

(16,322

Acquisitions of intangible assets

(96

(48

Other investing activities, net

60

346

Net cash used in investing activities

(4,704

(756

Financing Activities

Proceeds from short-term borrowings

6,397

2,022

Principal payments on short-term borrowings

(3,321

(16

Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less

(963

1,907

Proceeds from issuance of long-term debt

5,031

Principal payments on long-term debt

(4,317

(2,994

Purchases of common stock

(5,000

(6,160

Cash dividends paid

(5,496

(5,211

Proceeds from exercise of stock options

946

1,165

Other financing activities, net

29

171

Net cash used in financing activities

(6,693

(9,115

Effect of exchange-rate changes on cash and cash equivalents

(79

(162

Net decrease in cash and cash equivalents

(1,547

(244

Cash and cash equivalents, beginning

3,641

3,343

Cash and cash equivalents, end

2,094

3,099

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

1,430

1,414

Interest

1,177

1,162

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.

We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 28, 2016 and August 23, 2015. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 2, 2016 and September 27, 2015.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K.

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13.

In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets, Other noncurrent assets, Short-term borrowings, including current portion of long-term debt and Long-term debt, and in the condensed consolidated statement of cash flows for the nine months ended September 27, 2015, we performed certain reclassifications to conform to the current presentation of Other changes in assets and liabilities, net of acquisitions and divestitures, Principal payments on short-term borrowings, and Principal payments on long-term debt, for debt issuance costs in accordance with the adoption of a new accounting standard. For additional information, see Note 1B.

On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical will acquire all of Pfizer s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions, and devices. Pfizer has also agreed to certain restrictions on transfer of its ICU Medical shares for at least 18 months. Assets and liabilities associated with HIS were reclassified as held for sale in the condensed consolidated balance sheet as of October 2, 2016. The companies expect to complete the transaction in the first quarter of 2017, subject to customary closing conditions, including required regulatory approvals. For additional information, see Note 2B.

On September 28, 2016 (the acquisition date), we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ($13.9 billion, net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation, and, in accordance with our domestic and international reporting periods, our consolidated financial statements for the three and nine months ended October 2, 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)